［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］JIANG X,TANG H,CHEN T.Epidemiology of gynecologic cancers in China［J］.Journal of Gynecologic Oncology,2018,29(1):e7.
［3］KNISELY AT,CLAIR CMS,HOU JY,et al.Trends in primary treatment and median survival among women with advanced-stage epithelial ovarian cancer in the US from 2004 to 2016［J］.JAMA Network Open,2020,3(9):e2017517.
［4］KOBAYASHI-KATO M,YUNOKAWA M,BUN S,et al.Platinum-free interval affects efficacy of following treatment for platinum-refractory or-resistant ovarian cancer［J］.Cancer Chemotherapy and Pharmacology,2019,84(1):33-39.
［5］VAN ZYL B,TANG D,BOWDEN NA.Biomarkers of platinum resistance in ovarian cancer:what can we use to improve treatment［J］.Endocrine-Related Cancer,2018,25(5):R303-R318.
［6］YU H,JOVE R.The STATs of cancer-new molecular targets come of age［J］.Nature Reviews Cancer,2004,4(2):97-105.
［7］MCLEAN K,TAN L,BOLLAND DE,et al.Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth［J］.Oncogene,2019,38(9):1576-1584.
［8］SZEGEZDI E,FITZGERALD U,SAMALI A.Caspase-12 and ER-stress-mediated apoptosis:the story so far［J］.Annals of the New York Academy of Sciences,2003,1010:186-194.
［9］CHEN Q,XU B,LAN L,et al.High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer:a pooled meta-analysis［J］.Scientific Reports,2017,7(1):8769.
［10］HENGARTNER MO.Apoptosis:corralling the corpses［J］.Cell,2001,104(3):325-328.
［11］XU J,ZHANG J,MAO QF,et al.The interaction between autophagy and JAK/STAT3 signaling pathway in tumors［J］.Frontiers in Genetics,2022,13:880359.
［12］LIU Y,LIAO S,BENNETT S,et al.STAT3 and its targeting inhibitors in osteosarcoma［J］.Cell proliferation,2021,54(2):e12974.
［13］GEETHADEVI A,NAIR A,PARASHAR D,et al.Oncostatin M receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth［J］.Cancer Research,2021,81(20):5336-5352.
［14］PERMUTH-WEY J,FULP WJ,REID BM,et al.STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer［J］.International Journal of Cancer,2016,138(3):612-619.
［15］SZULC-KIELBIK I,KIELBIK M,NOWAK M,et al.The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells.Systematic review of its potential role as a biomarker in ovarian cancer patients［J］.Biochimica et Biophysica Acta Reviews on Cancer,2021,1876(2):188639.
［16］BIXEL K,SAINI U,KUMAR BID H,et al.Targeting STAT3 by HO-3867 induces apoptosis in ovarian clear cell carcinoma［J］.International Journal of Cancer,2017,141(9):1856-1866.
［17］RATH KS,NAIDU SK,LATA P,et al.HO-3867,a safe STAT3 inhibitor,is selectively cytotoxic to ovarian cancer［J］.Cancer Research,2014,74(8):2316-2327.
［18］SELVENDIRAN K,AHMED S,DAYTON A,et al.HO-3867,a curcumin analog,sensitizes cisplatin-resistant ovarian carcinoma,leading to therapeutic synergy through STAT3 inhibition［J］.Cancer Biol Ther,2011,12(9):837-845.
［19］SELVENDIRAN K,TONG L,BRATASZ A,et al.Anticancer efficacy of a difluorodiarylidenyl piperidone(HO-3867) in human ovarian cancer cells and tumor xenografts［J］.Molecular Cancer Therapeutics,2010,9(5):1169-1179.
［20］KRISHNAMURTHY N,KURZROCK R.Targeting the Wnt/beta-catenin pathway in cancer:Update on effectors and inhibitors［J］.Cancer Treatment Reviews,2018,62:50-60.
［21］BUGTER JM,FENDERICO N,MAURICE MM.Mutations and mechanisms of WNT pathway tumour suppressors in cancer［J］.Nature Reviews Cancer,2021,21(1):5-21.
［22］MORIN PJ.Beta-catenin signaling and cancer［J］.BioEssays,1999,21(12):1021-1030.
［23］SAHA S,PARTE S,ROY P,et al.Ovarian cancer stem cells:Characterization and role in tumorigenesis［J］.Advances in Experimental Medicine and Biology,2021,1330:151-169.
［24］JIANG W,FAN W,GAO T,et al.Analgesic mechanism of sinomenine against chronic pain［J］.Pain research & Management,2020,2020:1876862.
［25］GAO LN,ZHONG B,WANG Y.Mechanism underlying antitumor effects of sinomenine［J］.Chinese Journal of Integrative Medicine,2019,25(11):873-878.
［26］LI H,LIN Z,BAI Y,et al.Sinomenine inhibits ovarian cancer cell growth and metastasis by mediating the Wnt/β-catenin pathway via targeting MCM2［J］.RSC Advances,2017,7(79):50017-50026.
［27］ZHANG H,JIAO Y,SHI C,et al.Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/β-catenin signaling［J］.Acta Biochimica et Biophysica Sinica,2018,50(6):532-539.
［28］SZTURZ P,RAYMOND E,ABITBOL C,et al.Understanding c-MET signalling in squamous cell carcinoma of the head & neck［J］.Critical Reviews in Oncology Hematology,2017,111:39-51.
［29］BU R,UDDIN S,BAVI P,et al.HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma［J］.Laboratory Investigation,2011,91(1):124-137.
［30］HUNG TH,LI YH,TSENG CP,et al.Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines［J］.Cancer Gene Therapy,2015,22(5):262-270.
［31］KIM HJ,YOON A,RYU JY,et al.c-MET as a potential therapeutic target in ovarian clear cell carcinoma［J］.Scientific Reports,2016,6:38502.
［32］WU CC,WENG CS,HSU YT,et al.Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET［J］.Taiwanese Journal of Obstetrics & Gynecology,2019,58(1):145-152.
［33］DE LUCA A,MAIELLO MR,D'ALESSIO A,et al.The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways:role in cancer pathogenesis and implications for therapeutic approaches［J］.Expert Opinion on Therapeutic Targets,2012,16(Suppl 2):S17-27.
［34］YANG SH,SHARROCKS AD,WHITMARSH AJ.MAP kinase signalling cascades and transcriptional regulation［J］.Gene,2013,513(1):1-13.
［35］RAY J,CHEN Y,BHAT N,et al.Down regulation of MAPK signaling by cytotoxic human monoclonal antibody in epithelial ovarian cancer［J］.Gynecologic Oncology,2017,147(1):220.
［36］CHEN Y,BIEBER MM,BHAT NM,et al.Ovarian carcinoma glyco-antigen targeted by human IgM antibody［J］.PLoS One,2017,12(12):e0187222.
［37］HAZAFA A,REHMAN KU,JAHAN N,et al.The role of polyphenol(flavonoids) compounds in the treatment of cancer cells［J］.Nutrition and Cancer,2020,72(3):386-397.
［38］HOSSEINZADEH E,HASSANZADEH A,MAROFI F,et al.Flavonoid-based cancer therapy:An updated review［J］.Anti-cancer Agents in Medicinal Chemistry,2020,20(12):1398-1414.
［39］LIM W,SONG G.Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction［J］.Oncology Letters,2017,14(1):810-818.
［40］LIM WC,KIM H,KIM YJ,et al.Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells［J］.Bioorganic & Medicinal Chemistry Letters,2017,27(23):5337-5343.
［41］RAUF A,IMRAN M,BUTT MS,et al.Resveratrol as an anti-cancer agent:A review［J］.Critical Reviews in Food Science and Nutrition,2018,58(9):1428-1447.
［42］TYAGI A,SINGH RP,AGARWAL C,et al.Resveratrol causes Cdc2-Tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma OVCAR-3 cells［J］.Carcinogenesis,2005,26(11):1978-1987.
［43］LIN HY,DELMAS D,VANG O,et al.Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol［J］.Journal of Cellular Biochemistry,2013,114(8):1940-1954.
［44］SONG M,BODE AM,DONG Z,et al.AKT as a therapeutic target for cancer［J］.Cancer Research,2019,79(6):1019-1031.
［45］EDIRIWEERA MK,TENNEKOON KH,SAMARAKOON SR.Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:Biological and therapeutic significance［J］.Seminars in Cancer Biology,2019,59:147-160.
［46］HOXHAJ G,MANNING BD.The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism［J］.Nature Reviews Cancer,2020,20(2):74-88.
［47］HONIG A,HAHNE JC,MEYER S,et al.PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer［J］.Anticancer Research,2012,32(5):2035-2041.
［48］DING YH,ZHOU ZW,HA CF,et al.Alisertib,an Aurora kinase A inhibitor,induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells［J］.Drug Design,Development and Therapy,2015,9:425-464.
［49］FALCHOOK G,COLEMAN RL,ROSZAK A,et al.Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer:A randomized clinical trial［J］.JAMA Oncology,2019,5(1):e183773.
［50］TOMAO F,BENEDETTI PANICI P,TOMAO S.Paclitaxel and alisertib in recurrent ovarian cancer［J］.JAMA Oncology,2019,5(6):909-910.
［51］MATULONIS UA,SHARMA S,GHAMANDE S,et al.Phase Ⅱ study of MLN8237(alisertib),an investigational Aurora A kinase inhibitor,in patients with platinum-resistant or-refractory epithelial ovarian,fallopian tube,or primary peritoneal carcinoma［J］.Gynecol Oncol,2012,127(1):63-69.
［52］CUI ZY,PARK SJ,JO E,et al.Cordycepin induces apoptosis of human ovarian cancer cells by inhibiting CCL5-mediated Akt/NF-κB signaling pathway［J］.Cell Death Discovery,2018,4:62.